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Authors' Reply 
Sir, 
We thank Mr. Fligelstone and Mr. Salaman for their 
concern about the risk of causing pulmonary embo- 
lism by compression ultrasonography. As they state 
themselves, the risk is based an theoretical grounds. In 
our series we have not seen any complication from 
compression ultrasonography. In other large series, 1
the safety of compression ultrasonography as been 
well reported. In none of the series has an excess of 
pulmonary emboli using compression ultrasonog- 
raphy been described, so we can accept his method to 
be safe in the detection of acute proximal deep venous 
thrombosis. 
As for the risk of Homan's ign, in a large series of 
236 consecutive patients clinically suspected of deep 
venous thrombosis, we saw no pulmonary emboli 
following the performance of this clinical test. Statis- 
tical analysis revealed no significant association with 
deep venous thrombosis whatsoever. In our opinion, 
Homan's ign must be regarded as obsolete. 
j. P. J. Wester and O. J. A. Th. Meuwissen  
Nieuwegein,  The Netherlands 
Reference 
1 LENSING AWA, HIRSH J, BCJLLER HR. Diagnosis of deep-vein 
thrombosis. In: COLMAN RW, HIRSH J, MARDER Vl, SALZMAN EW, 
eds. Hemostasis and Thrombosis: Basic Principles and Clinical 
Practice, Third edtion. JB Lippincott Company, Philadelphia; 
1994: 1297-1321.1. 
Correspondence 
Sir, 
We read with interest the paper by Yusuf et al. 1 
concerning acclerated peripheral arterial thrombolysis 
using pulse-spray thrombolysis (PST). Another tech- 
nique for accelerated thrombolysis has previously 
been described using 2 5 mg boluses of tissue plasmino- 
gen activator (tPA). As part of an ongoing study 
comparing this technique with conventional throm- 
bolysis we have two patients who have undergone 
attempted lysis of the same lesion on different 
occasions using each technique. 
The first patient was a 66-year-old man with a 
2-year history of claudication at 300 metres that had 
worsened over the 2 weeks prior to consultation to20 
metres. A 15cm occlusion of his left superficial 
femoral artery (SFA) was demonstrated on angiog- 
raphy. Thrombolysis was attempted using an intra- 
arterial infusion of tPA running at 0.5 mg/h for 4 h. At 
the end of this time clearance of the thrombus had 
occurred and angioplasty of an underlying stenosis 
was performed. This resulted in initial improvement 
of symptoms and return of pedal pulses. However, 
over the next 3 weeks his symptoms returned and a 
further angiogram showed re-occlusion of the SFA. 
Thrombolysis was performed using four bolus injec- 
tions of 5 mg of tPA. After 45 min the thrombus had 
been cleared and angioplasty of the stenosis was 
performed again. Three months later his claudication 
distance was 300 metres (similar to before the first 
acute episode). 
The second patient was an 85-year-old man who 
had previously had a left above knee in situ femor- 
opopliteal vein graft. He was admitted with a 6-hour 
history of sudden onset of rest pain in the left leg. 
Clinical examination was suggestive of a thrombosed 
graft which was confirmed on angiography. Throm- 
bolysis was performed using three 5 mg boluses of tPA 
over 20min followed by an infusion at 3.5mg/h for 
3.5h. Lysis was complete after this time and no 
underlying cause was demonstrated. He had a small 
haematemesis that evening from a duodenal ulcer but 
settled without further intervention. One year later he 
presented with 11 days of rest pain. Clinical and 
radiological findings were similar to the first episode. 
Thrombolysis was performed using a tPA infusion of 
i mg/h  for 8 hours and 0.5mg/h for a futher 5h after 
which it was stopped because the patient had a small 
haematemesis. Complete clearance was demonstrated 
on angiography. He later required emergency surgery 
with evacuation of a retroperitoneal haematoma and 
suture of the vessel but died 3 days later following a 
myocardial infarction. 
In these patients bolus injection of thrombolytic 
agent increased the speed of clot lysis compared to 
conventional methods. Together with other centres in 
the Thrombolysis Study Group, we are presently 
conducting a prospective randomised controlled 
study to assess this further. Bolus injection offers an 
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alternative to PST as a method of accelerated throm- 
bolysis. However, side effects using this technique, 
such as haemorrhage and distal embolisation, may be 
increased. 3 This must be balanced against complica- 
tions due to prolonged catheter insertion using con- 
ventional techniques. Further evaluation of both 
methods of accelerated thrombolysis is therefore 
needed before they become the treatment of choice. 
T. A. Cook, B. D. Braithwaite, R. B. Galland 
and J. J. Earnshaw 
Reading and Gloucester, U.K. 
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LMWH In Vein Grafts 
Sir, 
Wilson et aI. 1 suggest that low molecular weight 
heparin (LMWH) administered to rabbits inhibits the 
development of intimal hyperplasia in arteries under- 
going vascular grafting. This finding is of considerable 
potential clinical relevance. A few comments may be 
of interest. 
Unfractionated heparin (UH), at concentrations 
achieved uring treatment, significantly enhances and 
induces platelet aggregation, in vitro, in samples 
obtained from patients with ischaemic heart disease 
(IHD) 2-4 or peripheral vascular disease (PVD). 5 In 
contrast, the addition of LMWH, or a LMW Hep- 
arinoid, did not reproduce this effect. 4'5 Similarl)~ the 
administration of UH, but not of a LMW Heparinoid, 
to healthy volunteers was associated with enhanced 
platelet aggregation. 6 Thus, platelets from patients 
that may require vascular surgery may be susceptible 
to stimulation by UH but not LMWH. Furthermore, 
platelet activation is associated with thrombus forma- 
tion as well as with the release of intraplatelet growth 
factors (e.g. PDGF, serotonin). Thus, in contrast to UH, 
LMWH administration pre-, intra- and postoper- 
atively is less likely to increase the release of these 
growth factors. In this context, it is relevant that 
although aspirin (a potent inhibitor of platelet aggre- 
gation) can prolong the life span of vascular grafts, it 
is ineffective if administered more than 2-3 days after 
surgery. 7 This observation suggests that decreasing 
platelet activity in the peri-operative p riod may be of 
considerable importance. 
In conclusion, LMWH use in patients undergoing 
vascular surgery may confer long-term benefits pro- 
vided bleeding is not a problem. 
D. E Mikhail idis and M. A. Barradas 
London, U.K. 
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